Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis

被引:42
|
作者
Niklinska, W
Burzykowski, T
Chyczewski, L
Niklinski, J [1 ]
机构
[1] Med Acad Bialystok, Dept Thorac Surg, Bialystok, Poland
[2] Med Acad Bialystok, Dept Histol, Bialystok, Poland
[3] Med Acad Bialystok, Dept Embryol, Bialystok, Poland
[4] Limburgs Univ Ctr, Ctr Stat, Diepenbeek, Belgium
[5] Marie Curie Sklodowska Canc Ctr, Warsaw, Poland
[6] Inst Oncol, Warsaw, Poland
[7] Med Acad Bialystok, Dept Clin Mol Biol, Bialystok, Poland
关键词
lung cancer; p53; VEGF; diagnosis; prognosis;
D O I
10.1016/S0169-5002(01)00346-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible asscociation with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5-8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%), 36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF (P < 0.001). The positive result of the p53 mutation increased the odds of observing a higher level of VEGF expression approximately 9.5 times (95% confidence interval: [3.44, 25.89]). In the univariate analysis of survival, increasing levels of VEGF expression were associated with poor prognosis (P < 0.001 for trend). In the multivariate analysis, after adjusting for the presence of a p53-gene mutation, gender, TNM stage and histological type, the prognostic effect of VEGF expression level was marginally non-significant (P=0.077). When the two-category quantification of the VEGF level was considered (low vs: intermediate/high), a marginally significant (P = 0.024), unfavorable effect of intermediate/high levels of VEGF expression, independent of the effect of the presence of a p53-gene mutation, was found. In conclusion, we found that the p53 mutation was closely related to VEGF expression. Additionally, we observed that an intermediate/high expression of VEGF might be a useful indicator of prognosis in NSCLC. This latter conjecture, suggested by an analysis of the data, ought however, to be independently verified in further studies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S59 / S64
页数:6
相关论文
共 50 条
  • [1] Vascular endothelial growth factor expression is regulated by the p53 function in non-small cell lung cancer
    Giatromanolaki, A
    Schiza, SE
    Koukourakis, MI
    Siafakas, NM
    O'Byrne, K
    Harris, AL
    Gatter, KC
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A209 - A209
  • [2] Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC)
    Oshika, Y
    Nakamura, M
    Tokunaga, T
    Ohnishi, Y
    Abe, Y
    Tsuchida, T
    Tomii, Y
    Kijima, H
    Yamazaki, H
    Ozeki, Y
    Tamaoki, N
    Ueyama, Y
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2390 - 2396
  • [3] Serum "Vascular Endothelial Growth Factor" (VEGF) levels in patients with non-small cell lung cancer (NSCLC)
    Demirkazik, A
    Özer, I
    Akbulut, H
    Arican, A
    Külah, E
    Acikgöz, N
    Icli, F
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S265 - S265
  • [4] Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer
    Maniwa, Y
    Yoshimura, M
    Obayashi, C
    Inaba, M
    Kiyooka, K
    Kanki, M
    Okita, Y
    [J]. CHEST, 2001, 120 (02) : 589 - 594
  • [5] Co-expression of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) predicts worse prognosis in stage I non-small cell lung cancer (NSCLC)
    Han, H
    Siegfried, JM
    Landreneau, RJ
    Santucci, TS
    Macherey, RS
    Raab, SS
    Silverman, JF
    [J]. MODERN PATHOLOGY, 2002, 15 (01) : 320A - 321A
  • [6] Co-expression of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) predicts worse prognosis in stage I non-small cell lung cancer (NSCLC)
    Han, H
    Siegfried, JM
    Landreneau, RJ
    Santucci, TS
    Macherey, RS
    Raab, SS
    Silverman, JF
    [J]. LABORATORY INVESTIGATION, 2002, 82 (01) : 320A - 321A
  • [7] p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland
    Niklinska, W
    Burzykowski, T
    Chyczewski, L
    Rusin, MR
    Furman, M
    Laudanski, J
    Chyczewska, E
    Sulik, M
    Niklinski, J
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2000, 9 (02) : 81 - 87
  • [8] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [9] Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis
    Bonnesen, Barbara
    Pappot, Helle
    Holmstav, Julie
    Skov, Birgit Guldhammer
    [J]. LUNG CANCER, 2009, 66 (03) : 314 - 318
  • [10] Vascular endothelial growth factor (VEGF) is an autocrine survival factor in non-small cell lung cancer
    Barr, M.
    Gately, K.
    O'Byrne, K.
    [J]. LUNG CANCER, 2012, 75 : S2 - S2